# Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

> **NCT00395018** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 109 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** entecavir

## Key facts

- **NCT ID:** NCT00395018
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2012-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395018, "Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00395018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*